Atorvastatin lactone-d5
目录号 : GC49421An internal standard for the quantification of atorvastatin lactone
Cas No.:125995-03-1
Sample solution is provided at 25 µL, 10mM.
Atorvastatin lactone-d5 is intended for use as an internal standard for the quantification of atorvastatin lactone by GC- or LC-MS. Atorvastatin lactone is an active metabolite of the HMG-CoA reductase inhibitor atorvastatin.1,2 It is formed from atorvastatin by the UDP-glucuronosyltransferase (UGT) isoforms UGT1A3 and UGT1A1 in insect cell-derived supersomes expressing the human enzymes, and hydrolyzes to form atorvastatin in human serum at room temperature.2,3 Atorvastatin lactone inhibits HMG-CoA reductase (IC50 = 0.007 µM for the rat liver enzyme).1 It also inhibits the cytochrome P450 (CYP) isoforms CYP2C9.1 and CYP2C9.3 (IC50s = 16.8 and 5.62 µM, respectively), as well as P-glycoprotein (P-gp; IC50 = 3.1-5.2 µM).4,5
1.Roth, B.D., Blankley, C.J., Chucholowski, A.W., et al.Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleusJ. Med. Chem.34(1)357-366(1990) 2.Schirris, T.J.J., Ritschel, T., Bilos, A., et al.Statin lactonization by uridine 5’-diphospho-glucuronosyltransferases (UGTs)Mol. Pharm.12(11)4048-4055(2015) 3.Jemal, M., Ouyang, Z., Chen, B.C., et al.Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometryRapid Commun Mass Spectrom.13(11)1003-1015(1999) 4.Shiozawa, A., Yamaori, S., Kamijo, S., et al.Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3)Drug Metab. Pharmacokinet.36100364(2021) 5.Bogman, K., Peyer, A.-K., TÖrÖk, M., et al.HMG-CoA reductase inhibitors and P-glycoprotein modulationBr. J. Pharmacol.132(6)1183-1192(2001)
Cas No. | 125995-03-1 | SDF | |
Canonical SMILES | O=C(C1=C(C(C)C)N(CC[C@H](C[C@@H](O)C2)OC2=O)C(C3=CC=C(F)C=C3)=C1C4=C([2H])C([2H])=C([2H])C([2H])=C4[2H])NC5=CC=CC=C5 | ||
分子式 | C33H28D5FN2O4 | 分子量 | 545.7 |
溶解度 | DMSO : 25 mg/mL (46.24 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.8325 mL | 9.1625 mL | 18.3251 mL |
5 mM | 0.3665 mL | 1.8325 mL | 3.665 mL |
10 mM | 0.1833 mL | 0.9163 mL | 1.8325 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet